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Wedescribe the design, synthesis, and characteriza-
tion of a heterobivalent ligand (HBL) system that
competitively inhibits allergen binding to mast cell
bound IgE antibody, thereby inhibiting mast cell de-
granulation. HBLs are composed of a hapten conju-
gated to a nucleotide analog allowing simultaneous
targeting of the antigen-binding site as well the ‘‘un-
conventional nucleotide binding site’’ on IgE Fab
domains. Simultaneous bivalent binding to both sites
provides HBLs with over 100-fold enhancement both
in avidity for IgEDNP (Kd = 0.33 mM) and in inhibition of
allergen binding to IgEDNP (IC50 = 0.45 mM) than the
monovalent hapten (Kd
mono = 41 mM; IC50
mono =
55.4 mM, respectively). In cellular assays, HBL2 effec-
tively inhibits mast cell degranulation (IC50 = 15 mM),
whereas no inhibition is detected by the monovalent
hapten. In conclusion, this study establishes the use
of multivalency in a novel HBL design to inhibit mast
cell degranulation.
INTRODUCTION
Allergy results from an abnormal response of the adaptive
immune system directed against noninfectious environmental
substances (allergens) (Galli et al., 2008). Mast cells are themajor
effector cells that mediate allergic responses. Cross-linking of
IgE bound to its high-affinity receptor (FcεRI) on the surface
with multivalent allergens results in activation due to aggregation
of FcεRIs (Metzger, 1992; Turner and Kinet, 1999). This FcεRI-
dependent activation of mast cells results in degranulation,
which causes secretion of preformed mediators that are stored
in cytoplasmic granules, such as vasoactive amines, neutral pro-
teases, proteoglycans, cytokines, and chemokines (Blank and
Rivera, 2006).
Specific inhibition of allergic response requires recognition of
the allergen binding IgE; therefore, in studies aiming to achieve
such selectivity, haptenic derivatives of allergens have been
used. In earlier examples, monovalent haptens have been tested
for their ability to selectively inhibit IgE cross-linking by multiva-Chemistry & Biology 18, 1179–118lent allergens. This approach, however, requires excessive
amounts of monovalent hapten to accomplish any inhibition
due to the short falling of monovalent binding affinity compared
to multivalent allergen avidity. (A hapten is a small monovalent
molecule that binds to an antibody but does not stimulate an
immune response.) Therefore, this approach has only resulted
in limited success (Gue´ant et al., 1999; Mertes et al., 2008;
Richter et al., 1981; Romano and Ventura, 2008; Salvin, 1971).
Ordinarily, use of multivalent versions of haptens results in
cross-linking of mast cell bound IgEs, initiating an allergic
response through the same mechanism as the natural allergen,
however, this effect has been shown to be reversed with the
use of long linkers (>5 nm) (Baird et al., 2003; Kane et al., 1988).
In this study, we incorporate multivalency in a novel design
to inhibit mast cell degranulation by inhibiting allergen binding
to IgE. Multivalent interactions provide higher affinity (termed
avidity) than individual binding moieties: this arises from the
combined synergistic binding affinity of the components (Kies-
sling et al., 2006; Mammen et al., 1998). Examples in literature
demonstrate that bivalent binding, as in the case of antibodies,
can strengthen avidity of interactions by up to six orders of mag-
nitude over monovalent binding (Bilgic¸er et al., 2007, 2009; Carl-
son et al., 2007; Wang et al., 2000; Wieslander et al., 1990). Liter-
ature also has several reports that demonstrate importance and
applications of multivalency in biological and synthetic systems
(Kane, 2006; Kitov et al., 2000; Rao et al., 2000; Tong et al., 2009;
Vance et al., 2008; Wolfenden and Cloninger, 2005; Yi et al.,
2007; Zhang et al., 2004). In our approach, we have designed
heterobivalent ligands of a haptenic derivative to simultaneously
target the antigen binding site on IgE, as well as the ‘‘unconven-
tional nucleotide binding site,’’ located proximal to the antigen
binding site on the Fab domain of IgE (Rajagopalan et al.,
1996). We predicted that the simultaneous bivalent binding to
both sites would provide heterobivalent ligands with enhanced
avidity and selectivity for IgE, necessary for competitive inhibi-
tion of allergen IgE binding (Figure 1).
The heterobivalent ligands have three moieties to consider in
design: the nucleotide analog, the hapten, and the linker. The
nucleotide-binding site was first described by Rajagopalan
et al. (1996). The authors describe the site to be in the ‘‘con-
served’’ region of the variable domain of murine immunoglobulin
Gs (Figure 2A), and they speculated that this site was likely
conserved in all isotypes of immunoglobulins. They also reported
that this site accommodated binding of one ATP (adenine)8, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1179
Figure 1. Inhibition of Mast Cell Degranulation
Using Heterobivalent Ligands
(A) Degranulation occurs when a multivalent antigen binds
to multiple IgE antibodies on the surface of mast cells
causing cross-linking of the IgE receptor, FcεRI, initiating
a signaling cascade that results in the release of histamine
and other inflammatory and cytotoxic molecules.
(B) Heterobivalent ligands were engineered to simulta-
neously bind to the antigen binding region and the nu-
cleotide binding pocket on the Fab domains of an IgE. Due
to the enhanced avidity of the heterobivalent ligand, it
inhibits the binding of the allergen to the surface bound IgE
thus preventing degranulation.
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Inhibiting Mast Cell Degranulationmolecule to each Fab with a dissociation constant of50 mM. To
find a more potent nucleotide analog, we performed a computa-
tional screening for appropriate candidates, as described in the
Experimental Procedures. We selected nitrofuran (NF)/IgEDNP
as our antibody/hapten pair, because IgEDNP is used in well-
establishedmodel systemswhere allergic responses are studied
(Andrews et al., 2007; Oliver et al., 1994). Once these two moie-
ties were selected, we experimentally screened for the linkers1180 Chemistry & Biology 18, 1179–1188, September 23, 2011 ª2011 Elsevier Ltd Allwith the desired length, flexibility, and chemistry
that aided the best binding.
Our studies establish that with the appro-
priate linker between the two binding moieties,
heterobivalent ligands are able to inhibit allergen
binding to IgE at >100-fold lower concentrations
than the corresponding monovalent hapten.
Engineered heterobivalent ligands based onhaptenic derivatives of allergens are therefore able to competi-
tively and selectively inhibit allergen binding to IgEs, in turn inhib-
iting FcεRI clustering and allergic response. Furthermore, the
concept presented in this study establishes usefulness for the
nucleotide-binding site on immunoglobulins in inhibiting mast
cell degranulation, a previously ignored binding site. We de-
scribe proof of principle studies for inhibition of allergic re-
sponses by use of heterobivalent ligands.Figure 2. Location of the Conserved Nucleotide
Binding Site in Antibodies
(A) Representative crystal structure of an IgG antibody
(PDB 1IGY). Enlarged view of the Fab region of an immu-
noglobulin with the antigen and nucleotide binding sites
labeled.
(B) Backbone alignment of nine IgE antibody structures
with the residues that make up the nucleotide binding
pocket shown. PDB numbers for the IgE crystal struc-
tures: 2VXQ, 2R56, 1OAQ, 1OAR, 1OAU, 1OAX, 1OAY,
1OAZ, and 1OCW.
(C) Backbone alignment of 18 IgG, IgM, and IgE antibody
structures with the residues of the nucleotide binding
pocket shown. The invariability of the side chain configu-
rations demonstrate that the nucleotide binding pocket is
conserved through these various isotypes of antibodies.
PDB numbers for the overlaid crystal structures are 1DN0,
1DQL, 2VXQ, 2R56, 1AE6, 1BBD, 1DBB, 1F58, 1GGB,
1HIM, 1IGF, 1IKF, 1MAM, 1MRD, 1NCD, 1Q9W, 1UZ8,
and 2IFF.
rights reserved
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The Nucleotide Binding Site on Immunoglobulins
The design of heterobivalent ligands described in this study is
based on targeting the nucleotide-binding site in IgE antibodies.
First, we confirmed that this site is conserved in a variety of
immunoglobulins through molecular modeling. To this end, we
performed a least-squares root-mean-square deviation super-
position of all Fab domain crystal structures of IgE antibodies
(total of 9) available in the RSCB Protein Data Bank (Figure 2B).
The overlaid structures show the framework region of the nucle-
otide binding region to be conserved throughout all IgE anti-
bodies. Additionally, because the nucleotide binding site is likely
conserved throughout all immunoglobulin isotypes, we overlaid
>260 immunoglobulin crystal structures, including IgE, IgG,
and IgM demonstrating that residues of the nucleotide binding
region are conserved throughout antibody isotypes. As a repre-
sentative group, in Figure 2C, we show 18 overlaid crystal struc-
tures from a collection of IgE, IgG, and IgM isotypes. Specifically,
our analysis revealed that four residues, namely two tyrosine
residues from the light chain, one tyrosine, and one tryptophan
residue from the heavy chain, are conserved in all immunoglob-
ulin isotypes. Furthermore, the conformations of these side
chains are also highly conserved in the available immunoglobulin
crystal structures (Figure 2).
Next, we determined an appropriate nucleotide analog. Ac-
cording to previously published results, adenine binds to the
nucleotide binding site with a Kd of 50 mM (Rajagopalan et al.,
1996). For our purposes, the nucleotide binding site targeting
moiety (nucleotide analog) must have the right affinity for this
site, such that, efficient binding to IgE antibodies is obtained
only when it is conjugated to the hapten. A nucleotide analog
with weak binding affinity would not result in the required en-
hancement in avidity of heterobivalent ligand binding. On the
other hand, extremely strong affinity would also not yield the
desired outcome, because, the nucleotide analog would bind
nonspecifically to all immunoglobulin isotypes regardless of the
presence or absence of the hapten as the nucleotide binding
site is conserved in all antibody isotypes. Given that only a small
minority of the antibodies in human plasma are IgEs, other iso-
types would act as a competitive sink for such heterobivalent
ligands. With these considerations in mind, we hypothesized
that a Kd of 1 mM (quite common for interactions between
immune components) would provide the optimal binding proper-
ties for the nucleotide analog—much tighter than that of ATP.
Therefore by use of computational methods (virtual screening
method), we examined a small library of commercially available
molecules similar to adenine to identify the analog that would
potentially have higher binding affinities to the nucleotide bind-
ing site (CAS numbers of the compounds screened were as
follows: 58944-73-3, 52562-50-2, 133-32-4, 575-85-9, 14490-
05-2, 2338-71-8, 4771-50-0.). Results of this screen predicted
that indole-3-butyric acid (IBA) would bind with the highest
affinity of the compounds screened. The binding affinity of IBA
to the IgEDNP was determined experimentally using the fluores-
cence quenching method. The IBA derivative that was used in
this titration, ML2, was synthesized by conjugating IBA to 5-
((2-aminoethyl)amino)naphthalene-1-sulfonic acid (EDANS).
The EDANS excitation wavelength overlaps with the tryptophanChemistry & Biology 18, 1179–118emission wavelength; therefore this system provided us a
method to determine IBA binding to IgEDNP by fluorescence
quenching. These experiments yielded a binding constant of
4.5 ± 0.6 mM forML2 and IgEDNP. Our control experiments estab-
lished that EDANS does not bind IgEDNP (see Figure S1 available
online).
Model IgE/Hapten System
The dinitrophenyl/anti-DNP IgE (DNP/IgEDNP) is the most com-
monly used hapten/antibody system to study allergic re-
sponses. The drawback of this system is that DNP binds to
IgEDNP with an atypically highmonovalent binding affinity (James
et al., 2003). Therefore, we decided to use a variant of the DNP/
IgEDNP system: the NF/IgEDNP pair. Based on crystal structure
analysis, NF was not expected to cause steric problems such
as occupying the nucleotide-binding site as would be the case
for DNP (James et al., 2003). With these design tenets in mind,
the NF/IgEDNP pair was chosen as an appropriate model system
to carry out the proof of principle experiments described in this
study. We used a fluorescence quenching method for the NF
hapten system to determine binding constants to IgEDNP. The
absorbance profile of NF overlaps with the fluorescence emis-
sion of the tryptophans in IgEDNP. This overlap provides a
straightforward spectroscopic method to directly measure the
extent of association between NF and IgEDNP. Upon binding of
NF to IgEDNP, fluorescence from the IgEDNP tryptophan residues
is quenched, and using this method, we determined that NF
binds to IgEDNP with a binding constant (Kd) of 41 ± 3 mM (ML1
in Table 1; see Experimental Procedures for detailed equations).
Optimization of Heterobivalent Ligands and
Thermodynamic Analysis of IgE-Heterobivalent Ligand
Interactions
Next we synthesized the heterobivalent ligands of NF-IBA with
various linker molecules using solid phase synthesis. We deter-
mined the binding constants of heterobivalent ligands listed in
Table 1 to IgEDNP using fluorescence quenching. As can be
seen from the measured binding constants, linker length and
flexibility play a very important role. The heterobivalent ligand
that had the lowest Kd (0.33 ± 0.07 mM) was HBL2, where the
linker was six repeating units of ethylene glycol (EG6). Ethylene
glycol linkers have high water solubility (lowest hydrophobicity)
and good flexibility. The next three tight binders were also
ethylene glycol linkers with slightly shorter (EG5), slightly longer
(EG8), and much longer (EG24) lengths with Kd 0.79 ± 0.06 mM
(HBL1), 0.55 ± 0.03 mM (HBL3), and 0.96 ± 0.05 mM (HBL4)
respectively, establishing the importance of proper linker length.
Increase in the hydrophobicity of the linker by using ε-linked
lysine residues resulted in diminution of binding avidities as
seen for molecules HBL5 and HBL6, whose Kd values were
determined to be 30 ± 3 mM and 15 ± 1 mM. Furthermore,
increasing the rigidity of the linker by incorporating 4-carboxy
piperidine in the linkers did not yield favorable results. Specifi-
cally, increasing the number of 4-carboxy piperidine from 1 to
4 (HBL7-10), yielded Kd 1.6 ± 0.2 mM, 1.9 ± 0.2 mM, 2.0 ±
0.2 mM, and 15 ± 1 mM. In summary, the most effective heterobi-
valent ligand was HBL2, synthesized using EG6 as the linker.
Representative binding curves of HBL2 to IgEDNP are shown in
Figure 3A. This molecule shows a 124-fold enhancement over8, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1181
Table 1. Structures of the ML and HBL Ligands with Their Corresponding Extended Length and Apparent Affinities for IgEDNP
Molecule Structure Length (A˚) Kd (mM)
ML1 N/A 41 ± 3
ML2 N/A 4.5 ± 0.6
HBL1 (n = 5) 25 0.79 ± 0.06
HBL2 (n = 6) 28.5 0.33 ± 0.07
HBL3 (n = 8) 34 0.55 ± 0.03
HBL4 (n = 24) 92 0.96 ± 0.05
HBL5 (n = 2) 26.7 30 ± 3
HBL6 (n = 3) 34 15 ± 1
HBL7 32.2 1.6 ± 0.2
HBL8 33.1 1.9 ± 0.2
HBL9 36.8 2.0 ± 0.2
HBL10 29.5 15 ± 1
HBL, heterobivalent; ML, monovalent; N/A, not applicable. The linkers for HBL1-4 have polyethylene glycol linkers of different length, HBL5-6 have
ε-linked lysine residues that are more hydrophobic than ethylene glycol, and HBL7-10 incorporate rigid carboxy piperidine residues.
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Figure 3. HBL2 Binds to IgEDNP with 124-Fold
Affinity over ML1
(A) Representative binding curves for HBL2 (-), mono-
valent NF (ML1:B), andmonovalent IBA (ML2:;) binding
to IgEDNP. Binding was observed by monitoring fluores-
cence quenching of tryptophan as described in the
Experimental Procedures section. Values for the various
molecules: Kd
HBL2 = 0.33 ± 0.07 mM, Kd
ML1 = 41 ± 3 mM,
and Kd
ML2 = 4.5 ± 0.6 mM. In a separate experiment
EDANS did not bind to IgEDNP over this concentration
range (Figure S1).
(B) Effective inhibitory concentrations of monovalent NF
(ML1: B) and HBL2 (-) were compared in an ELISA
assay. BSA conjugated nitrofuran was adsorbed onto the
surface of a 96-well plate and increasing concentrations of
either HBL2 or ML1 were incubated with IgEDNP antibody
prior to the addition to the wells. Inhibition was measured
by monitoring the activity of HRP conjugated to a sec-
ondary antibody (anti-mouse IgE from goat). IC50
HBL2 =
0.45 ± 0.05 mM and the IC50
ML1 = 55 ± 5 mM. The error
bars are standard deviations from at least triplicate
measurements.
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that of monovalent IBA (ML2). Therefore, we predicted that
HBL2 would be the most potent heterobivalent ligand in the inhi-
bition studies.
Heterobivalent Ligands Competitively Inhibit Allergen
Binding to IgE Antibody
Allergic reactions are elicited when a multivalent allergen medi-
ates clustering of the FcεRI-bound IgE molecules on the surface
of mast cells. To simulate binding of multivalent allergens to IgEs
in our experimental system, we synthesized multivalent bovine
serum albumin (BSA) NF-BSA in order to mimic allergens.
Mass spectrometric analysis showed an average of 17 NF mole-
cules per BSA in NF-BSA conjugates (see Experimental Proce-
dures). We then used a competitive binding enzyme-linked
immunosorbent assay (ELISA) to evaluate the efficacy of the het-
erobivalent ligand HBL2 in inhibiting binding of NF-BSA to
IgEDNP. For this purpose, we incubated IgEDNP with increasing
concentrations of HBL2 in a 96-well plate coated with NF-BSA
until equilibrium was reached. According to our results, HBL2 in-
hibited the binding of IgEDNP to NF-BSA with an IC50 of 0.45 ±
0.05 mM, whereas 55 ± 5 mM of monomeric NF (ML1) was
required to achieve 50% inhibition (Figure 3B). In a similar set
of experiments performed using the nucleotide analog, IBA, we
did not observe any inhibition of NF-BSA binding to the IgEDNP.
These results mirrored the findings of the thermodynamicChemistry & Biology 18, 1179–1188, September 23,binding constants where HBL2 had greater
than two orders of magnitude higher binding
affinity for IgEDNP over that of monovalent NF.
Heterobivalent LigandsEffectively Inhibit
Mast Cell Degranulation
To assess the potential of HBL2 to inhibit the
degranulation response, we used a well-estab-
lished rat basophilic leukemia (RBL) cell model
system (Blank and Rivera, 2006; Posner et al.,
2002). These cells have FcεRI receptors on theirsurfaces that have a high affinity for IgEDNP. It has been previ-
ously shown that aggregation of IgEDNP antibodies bound to
the FcεRI receptors on RBL cells by DNP-BSA results in
a degranulation response with a mechanism similar to degranu-
lation of mast-cells. To adapt the RBL cell model system for our
purpose, we optimized the system to achieve a degranulation
response by NF-BSA. We first incubated RBL cells with mono-
clonal mouse IgEDNP to allow the antibody to bind to FcεRI on
cell surfaces. Cells were then exposed to NF-BSA in increasing
concentrations to crosslink the surface bound IgEDNP anti-
bodies, which in turn stimulate degranulation. We determined
that >90% degranulation was achieved at 100 mg/ml NF-BSA,
with an EC50 of 50 mg/ml (Figure 4A). Next, to evaluate the
inhibitory effect of heterobivalent ligands, we co-incubated
RBL cells with NF-BSA and increasing concentrations of
HBL2. As can be seen in Figure 4B, HBL2 significantly inhibited
the degranulation response induced by NF-BSA, with an IC50 of
15 ± 2 mM. As expected the IC50 is higher than the Kd because
only between 1%–10% of the FcεRI need to be cross linked to
initiate degranulation (Holowka and Baird, 1996). We did not
detect any inhibition by the monovalent NF at the concentrations
tested (Figure 4B), highlighting the remarkable enhancement ob-
tained in the binding affinity to IgE antibody by the heterobivalent
ligand. Our control experiments established that HBL2 did not
have any cytotoxic effects on the RBL cells, showing that the
inhibition of degranulation was by blocking RBL activation and2011 ª2011 Elsevier Ltd All rights reserved 1183
Figure 4. HBL2 Successfully Inhibits Mast Cell Degranulation
(A) Dose response of RBL mast cell degranulation in response to increasing concentrations of NF-BSA. Triton X (1%) was used to normalize the percent
degranulation in response to NF-BSA.
(B) Inhibitory potentials of monovalent NF (ML1:B) and HBL2 (-) were compared in a cellular assay by measuring the activity of b-hexoamidase, an enzyme
released during RBL degranulation (Blank and Rivera, 2006). Cells were first treated with saturating concentrations of IgEDNP, and were then activated by NF-
BSA. The IC50 of HBL2 was determined to be 15 ± 2 mM and no inhibition was observed over this range with ML1. In separate experiments IBA did not inhibit
degranulation (Figure S2) and the necessity of the antigen binding moiety was demonstrated (Figure S3). The error bars are standard deviations from at least
triplicate measurements.
Chemistry & Biology
Inhibiting Mast Cell Degranulationnot due to cytotoxic effects. Furthermore, we synthesized and
tested a HBL molecule where the IBA moiety on HBL2 was re-
placed with dansyl, a structurally similar molecule to IBA but
does not bind to the nucleotide binding site. In vitro cellular
assays established that this test molecule did not inhibit degran-
ulation (Figure S2). We also tested HBL2 for its potential to inhibit
degranulation in a dansyl allergy system, where anti-dansyl IgE
(IgEDansyl) was bound to mast cell FcεRIs, and dansyl-BSA was
used as the synthetic allergen. As expected, HBL2 did not inhibit
degranulation with this system (Figure S3). Together these
control experiments illustrate that bivalent binding of the HBL
molecules was indeed the only mechanism by which RBL
degranulation was inhibited.
Five more HBL molecules were assessed for their inhibitory
potential in RBL degranulation assays. HBL1 and HBL3 showed
similar inhibitory effects as HBL2, whereas HBL4 and HBL5 did
not have any inhibitory effect (Figure S4). These results were in
agreement with measured affinities of these HBLs for IgEDNP
and confirmed our prediction that higher avidity would directly
correlate with better inhibitory effect.DISCUSSION
The described studies represent part of our continuing effort to
develop heterobivalent ligands that selectively bind to target
IgE antibodies with high avidity to competitively inhibit allergen
binding, and thereby inhibiting allergic reaction. Inhibition of
allergic response using monovalent haptens has not been
successful as the affinity of the monovalent hapten falls short
in comparison to the avidity of the multivalent allergen. Here,
we employ a novel approach, in order to increase avidity (rather
than affinity) in the design of heterobivalent ligands that compet-
itively bind to IgEDNP with high specificity and avidity.
Multivalent interactions provide enhanced binding avidity as
a result of increased effective molarity. Because the binding1184 Chemistry & Biology 18, 1179–1188, September 23, 2011 ª201components are linked to each other, the initial binding event
brings all the other interacting components into proximity; hence
the penalty for the translational entropy is prepaid by conjugating
binding entities to each other. We calculated the effective
molarity for the binding of the hapten component of HBL2 using
the equilibrium scheme described in Figure 5, and Equations 1
and 2 below:
KObsd =K
Ant
d 3 J
Nuc =KNucd 3K
Ant (1)
and
Ceff =K
Ant
d 3 J
Ant: (2)
Wedetermined thatCeff for theNFbinding inHBL2was562mM.
Hence to compete off half of HBL2 from binding to IgEDNP, this
is the necessary concentration of monovalent NF that is needed.
In order to better understand the effects of linker length on
binding, we started out by testing ethylene glycol linkers with
various lengths. Ethylene glycol (EG) polymers are hydrophilic,
flexible, and do not form specific interactions with proteins (Del-
gado et al., 1992; Harris and Chess, 2003; Roberts et al., 2002).
The first four heterobivalent ligands we synthesized had varying
lengths of EG linkers: HBL1 (EG5) was 2.5 nm, HBL2 (EG6) was
2.9 nm, HBL3 (EG8) was 3.4 nm long, and HBL4 (EG24) was
9.2 nm long. Analysis of the relative binding constants provide
information about the distance between the binding sites.
HBL1 had a Kd of 0.79 ± 0.06 mM, which suggested a weaker
binding interaction than HBL2 (Kd = 0.33 ± 0.07 mM). This result
suggested that the length of EG5 linker did not provide the
optimal length for binding of bothmoieties simultaneously. Using
the longer linker, EG8, in HBL3 resulted in a slight weakening of
the affinity (Kd = 0.55 ± 0.03 mM) compared to HBL2. The ligand
HBL4 with the longest linker, EG24, had even weaker binding
affinity (0.96 ± 0.05 mM). The decrease in the affinities of HBL3
and HBL4 is due to the increased conformational entropy of
the heterobivalent molecules as a result of the increase in the1 Elsevier Ltd All rights reserved
Figure 5. Bivalent Binding Enhances Ligand Avidity
Reaction equilibria for the binding of heterobivalent ligands to IgEDNP. The
Kd
Obs are the reported binding constants for the heterobivalent ligands listed in
Table 1. Kd
Ant is the dissociation constant of monovalent hapten (ML1), and
Kd
Nuc is the dissociation constant of monovalent nucleotide analog (ML2). JAnt
and JNuc are the unitless intramolecular binding constants for antigen and
nucleotide analog respectively. We calculated the values for these constants
to be JNuc = 0.008 and JAnt = 0.073 for HBL2 binding to IgEDNP.
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ethylene glycol linkers, we conclude that the optimal linker length
is 3 nm.
Next, we tested the effect of linker hydrophobicity on the over-
all avidity. Because both the nucleotide and the antigen binding
sites are sandwiched between the heavy and light chains of the
Fab region with several hydrophobic contacts, we expected that
a more hydrophobic linker would interact favorably with the anti-
body surface and increase the binding thermodynamics of the
ligands. The results, however, were just the opposite of our pre-
dictions. Heterobivalent molecules HBL5 and HBL6, with flexible
hydrophobic linkers of different lengths had binding constants of
30 ± 3 mMand 15 ± 1 mM respectively. The weaker binding ligand
HBL5 had a shorter linker length, suggesting that the optimal
linker length for this linker needed to be longer than 2.67 nm.
Nevertheless, even ligand HBL6, the more favorable of the
two, had a 50-fold weaker binding affinity compared to HBL2.
In fact, this binding affinity is still weaker than the monovalent
IBA (ML2), which had a Kd = 4.5 ± 0.6 mM. We hypothesize that
the reason for this weakened affinity is due to unfavorable inter-
actions between the linker and the antibody surface, or possibly
that the linker might be folding onto itself resulting in the weak-
ened binding to the antibody.
In order to investigate the effects of linker flexibility on binding
affinity, we synthesized another series of hydrophobic com-
pounds with increasing rigidity, molecules HBL7, HBL8, HBL9,
and HBL10. Hypothetically, increasing rigidity of the linker
should result in decreased penalty for conformational entropy
upon binding, with an effect similar to the observed decrease
in affinity with increased ethylene glycol linker length. Therefore,
the more rigid the linker, the more favorable the interaction
should be. The results of the binding constants for this series,
however, show just the opposite trend. This is possibly a result
of two effects: (1) the rigid linker monomer we used was highly
hydrophobic, and as we learned from the earlier series of com-
pounds, increased hydrophobicity did not result in a favorable
binding interaction; and (2) the six-membered cyclic ring struc-Chemistry & Biology 18, 1179–118ture was possibly too rigid to accommodate the binding of
both groups simultaneously in the correct geometry. The binding
affinities of the compounds in this series (HBL7-10) varied
between 15 ± 1 mM to 1.6 ± 0.2 mM, about an order of magnitude
separating the best binding (HBL7; Kd = 1.6 ± 0.2 mM) and the
worst binding (HBL10; Kd = 15 ± 1 mM) ligands. HBL7, however,
still hadweaker affinity than ligandHBL2, which again suggested
that the surface of the antibody did not favor hydrophobic inter-
actions with the linker moieties. Results of the thermodynamic
analysis of the heterobivalent molecules established that ligand
HBL2 had the highest potential to successfully inhibit antibody/
allergen interaction in competitive binding experiments.
In summary, increasing the avidity of the hapten by conju-
gating a nucleotide binding site targeting moiety with an appro-
priate linker provided very favorable results for inhibiting the IgE/
allergen interaction. In the ELISA binding assay, heterobivalent
ligand HBL2 had an IC50 of 0.45 ± 0.05 mM for inhibiting the
binding of the allergen mimic (NF-BSA) to IgEDNP, whereas the
IC50 of monovalent NF was 55 ± 5 mM (Figure 3B). More remark-
ably, in the in vitro cellular degranulation assay, we determined
that HBL2 had an IC50 of 15 ± 2 mM, whereas we did not observe
any inhibition by the monovalent hapten even at the elevated
concentrations in the titration (Figure 4B). We believe that the
relativeweak affinity of the hapten (Kd = 41± 3 mM) had a negative
effect on the increase in avidity, as, in principle, a heterobivalent
molecule synthesized with a higher affinity hapten would have
yielded an enhancement in binding higher than that was ob-
served in the described system.
Weestablish in this studya formerly unexploredpractical use for
the unconventional nucleotide binding site on the immu-
noglobulins that paves the way for a molecular engineering
approach to selectively inhibit allergic response. The potential
for using heterobivalent ligand design in allergic response inhibi-
tion will increase as knowledge of immune epitopes increases
and the significance of certain epitopes in specific allergies
becomes clearer. Meanwhile, this approach of targeted inhibition
is readily applicable to allergies where the allergen is a small well-
definedmolecule suchas in allergies tob-lactamantibiotics or any
in the class of sulfonamidedrugs. Specifically, our technology has
the potential to greatly increase the effectiveness of haptenic
derivatives of penicillin as it has been shown that such molecules
are able to inhibit IgE-penicillin interaction albeit in very high
concentrations (Fernandez et al., 1995; Zhaoet al., 2001). Further-
more, our approach has broad application in inhibiting food aller-
gies, environmental allergies, and asthmas. A critical component
for the success of this approach in such allergies is the identifica-
tion of allergy epitopes. Currently, there is significant effort for the
identification and characterization of various epitopes in the
allergy field; several research groups have identified some of
the most frequent reactive sites on common allergens using high
through-put screening techniques such asphage display, peptide
microarrays, and molecular modeling (Cerecedo et al., 2008; Pa-
cioset al., 2008;Riemeret al., 2004;Rouge´ et al., 2009;Tordesillas
et al., 2010). Increasing amounts of data are becoming available
due to the technological advances in epitopemapping techniques
and establishment of centralized databases such as Immune
Epitope Database (Vita et al., 2010). Identification of these sites
provides a starting point for the design of heterobivalent ligands
that can be used in specific inhibition of a particular allergy.8, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1185
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One of the challenges in the current therapies used to
treat adverse immunological responses such as allergies is
the nonspecific suppression of immune system that puts
patients at increased risk for infections and even develop-
ment of cancers. This underlines the need to develop more
specific treatments for such adverse immunological re-
sponses without the overall suppression of the immune
system.Here,byusingavariantof an IgE/DNPmodel system,
we demonstrate the proof of principle studies of a new
approach that has the potential to respond to this need by
selectively inhibiting mast cell degranulation. Specifically,
we designed heterobivalent ligands that simultaneously
bind to two nearby sites located on the Fab domains of IgE
molecules—the antigen binding and the nucleotide binding
sites. These dual targeting molecules have enhanced avidity
and selectivity for a target IgE antibody. The heterobivalent
ligands showed up to 124-fold higher affinity for the specific
IgE compared to monovalent hapten, and successfully in-
hibited mast cell degranulation whereas the monovalent
hapten did not show any inhibition even at elevated concen-
trations. The described method of targeted inhibition can
have broad applications in inhibiting food allergies, environ-
mental allergies, and asthmaswhere the allergy epitopes are
known. As an example, the design can be applied to inhibit
allergies caused by b-lactam antibiotics or any in the class
of sulfonamide drugs where the allergen is a well-defined
small molecule. Finally, this study establishes, for the first
time, a newpractical use for the previously neglected uncon-
ventional nucleotide binding site found on the Fab domain of
immunoglobulins.
EXPERIMENTAL PROCEDURES
Materials
We purchased N-Fmoc-amido-dPEG8-acid and N-Fmoc-amido-dPEG24-acid
from Quanta BioDesign, Fmoc-NH-(PEG)4-COOH, Fmoc-NH-(PEG)5-COOH,
N-Fmoc-amino acids, Fmoc-lys(ivDde)-OH, NovaPEG Rink Amide resin,
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
(HBTU), and BSA from EMD Biosciences. Indole-3-butyric acid, 5-nitro-2-
furoic acid, N,N-diisopropylethylamine (DIEA), N-(3-dimethylaminopropyl)-
N0-ethylcarbodiimide (EDC), trifluoroacetic acid (TFA), and piperidine from
Sigma and N,N-dimethylformamide (DMF) (>99.8%) were purchased from
Thermo Fisher. IgEDNP was a monoclonal IgE isolated from ascites, and was
purified using a trinitrophenyl-lysine affinity column.
Design of the Heterobivalent Ligand
The heterobivalent ligand has three important components that contribute to
binding avidity: (1) the hapten, (2) the nucleotide analog, and (3) a linker connect-
ing these two moieties. The hapten and the nucleotide analog were chosen
based on the criteria described above. Next we screened for the linker with
optimal properties. Three properties are important when choosing the appro-
priate linker: length, flexibility, and chemistry (hydrophobicity, polarity, charge,
and H-bonding capability). Upon analyzing the crystal-structure of the Fab
domain of an IgEDNP antibody (Protein Data Bank [PDB] 2r56), the shortest
distance between the antigen-binding and the nucleotide-binding sites was
found to be >2.5 nm.We took this distance as theminimum linker length neces-
sary to span the twosites. Flexibility is another important parameter for the linker
such that it can conform to the surface topology of the IgEDNP and not cause
steric impediments to binding. The chemical properties of the linker are yet
another set of important parameters: favorable interactions between the linker
and the surface of the IgE that span the antigen-binding site and the nucleotide1186 Chemistry & Biology 18, 1179–1188, September 23, 2011 ª201binding site would bemanifested as an increased overall avidity of the heterobi-
valent ligand to the IgE. Therefore,wescreenedmultiple linkersexperimentally to
determine their effect on the avidity of the heterobivalent ligands to IgEDNP. Each
heterobivalent ligand linker has unique properties and the same pair of hapten
and nucleotide analog attached allowing us to decipher the optimal properties
for the linker yielding the heterobivalent ligand with the best binding avidity.
Synthesis of Heterobivalent Ligands
The heterobivalent ligands were synthesized using Fmoc chemistry on a solid
support. Residues were activated with HBTU and DIEA in DMF for 3 min and
coupling completion was monitored with Keiser tests. The Fmoc protected
residues were deprotected using 3 3 20% piperidine in DMF for 3 min. After
the addition of indole-3-butyric acid the ivDde protecting groupwas selectively
removed from the lysine residue using 3 3 2% hydrazine in DMF for 3 min
providing a free amine for the addition of 5-nitro-2-furoic acid. The ligands
were cleaved from the solid support using 2 3 92/4/4 TFA/H2O/TIS for
30 min. We purified the heterobivalent ligands using RP-HPLC on an Agilent
1200 series system with a semi-preparative Zorbax C18 column (9.4 mm 3
250mm), using linear solvent gradients of 2.5%min1 increments in acetonitrile
concentration at 4.0 ml/min flow rate. We monitored the column eluent with
a diode array detector allowing a spectrum from 200 to 400 nm to be analyzed.
The purified product was characterized using aBrukermicrOTOF IImass spec-
trometer and a Varian UnityPlus 300 NMR (Supplemental Information). The
purity of all synthesized ligands was estimated to be >97% by an analytical
injection using the above describedHPLCwith a Zorbax C18 analytical column
(4.6mm3 150mm). The calculatedmolecularmass ofML1 (C24H41N5O11) was
575.3 Da; found 576.3 Da (with sodium adduct at 598.3 Da), the calculated
molecular mass of ML2 (C40H53N10O10S1) was 865.4 Da; found 866.4 Da
(with sodium adduct at 888.4 Da), the calculated molecular mass of HBL1
(C42H62N6O8) was 760.4 Da; found 761.4 Da (with sodium adduct at
783.4 Da), the calculated molecular mass of HBL2 (C38H56N6O13) was
804.4 Da; found 805.4 Da (with sodium adduct at 827.4 Da), the calculated
molecular mass of HBL3 (C42H64N6O15) was 892.4 Da; found 893.4 Da (with
sodium adduct at 915.4 Da), the calculated molecular mass of HBL5
(C41H62N10O9) was 838.5 Da; found 839.5 Da (with sodium adduct at
861.5 Da), the calculated molecular mass of HBL6 (C47H74N12O10) was
966.6 Da; found 967.6 (with sodium adduct at 989.6 Da), the calculatedmolec-
ular mass of HBL7 (C43H62N8O10) was 898.4 Da; found 899.4 Da (with sodium
adduct at 921.4), the calculated molecular mass of HBL8 (C51H74N10O15) was
1066.5 Da; found 1067.5 Da (with sodium adduct at 1089.5 Da), the calculated
molecular mass of HBL9 (C49H71N9O14) was 1009.5 Da; found 1010.5 Da (with
sodium adduct at 1032.5 Da), the calculated molecular mass of HBL10
(C69H105N11O20)was1407.7Da; found1408.7 (with sodiumadductat1430.7Da).
Synthesis of Conjugated BSA
BSA (10mg) was dissolved in 1ml of MESbuffer (0.1M pH 4.7), 4 mg of 5-nitro-
2-furoic acid was dissolved in 1ml ofMES buffer, EDC (10mg) was dissolved in
100mL ofMESbuffer and immediately added to a solution of 200mL of BSA, and
500 mL of 5-nitro-2-furoic acid. Fresh EDC was added every 45 min until the
desired number of nitrofuranswere conjugated to BSA. Conjugation wasmoni-
toredusingSE-HPLCon anAgilent 1200 series systemwith a TosohBioscience
TSKgel Super SW3000 column (4.6mm3 300mm) at 0.25ml/min PBS (pH 6.8)
and characterized using a Bruker AutoFlex MALDI TOF/TOF. The conjugated
BSA was purified using a Corning Spin-X UF concentrator with a 30 kDa
membrane. The purity of NF-BSA (elution time 10.7 min) was estimated to be
>95%using theSE-HPLCmethoddescribedearlierwhere theonly contaminant
detected was unreacted excess NF at <5% (elution time 15.2 min). The molec-
ular mass of unmodified BSA was 66869.4 Da (with double charged peak at
33492.9m/z), and theNF-BSAhadamolecularmassof 68940.5Da (withdouble
charged peak at 34800.2 m/z) indicating an average addition of 17 NF mole-
cules per BSA. Additionally the purified NF-BSA was lyophilized allowing us
to determine the amount of protein by mass and concentration of NF by absor-
bance. The number of NF/BSAdetermined using thismethodwas in agreement
with the number of NF/BSA determined by mass spectometry.
Fluorescence Quenching Assay
NF has amaximumabsorbance at 314 nm,whereas tryptophan fluorescence is
at 335 nm. The overlap in NF absorbance and tryptophan fluorescence1 Elsevier Ltd All rights reserved
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extent of association between the heterobivalent molecules and the IgEDNP.
Upon heterobivalent molecule binding to the IgEDNP, the fluorescence from
the IgEDNP tryptophan residues were quenched by the nitrofuran. To determine
the binding constants of nucleotide analogs, we conjugated the molecule to
EDANS (max absorbance 335 nm), which also quenches the fluorescence of
tryptophan residues. The binding constant (K0d) can be calculated from
Equation 3,
K0d =
½IgE½L
½IgE L ; (3)
where L is the ligand. When the starting IgEDNP concentration is significantly
below the value of Kd ([IgE
DNP] < Kd), then upon binding to the antibody the
free ligand concentration in solution does not change. By dividing the
measured fluorescence (F) to the fluorescence in the absence of ligand (Fo),
the effect of quenching can be normalized. Hence, K0d becomes equal to
concentration of L at the deflection point of the titration sigmoid for (F/Fo)
versus [L]. Therefore, rearranging Equation 3 yields Equation 4. Kd can be
calculated from Equation 4,
F
Fo
= 1
 ½L
ð½L+KdÞ

: (4)
We normalized the measured fluorescence using Equation 5,
F
Fo
=
½Fa;[;PBS  F[;PBS
½Fa;PBS  FPBS ; (5)
where F denotes the measured fluorescence at 335 nm, and the subscripts
indicates the compounds that are also present in the sample, where a is
IgEDNP, [ is the ligand being analyzed for binding, and PBS is the buffer. At
high concentrations of ligand the fluorescence of the tryptophan residues in
the antibody can be quenched by ligands that are in proximity to the IgE
although they may not be forming any interactions with it. This is due to fluo-
rescence quenching efficiency being based on proximity of the donor mole-
cule to the acceptor molecule. As the concentration of the ligand increases
the statistical probability of finding a quencher molecule close to the donor
significantly increases. To account for the random quenching an extra term
was added to Equation 5 yielding Equation 6,
F
Fo
=
½Fa;[;PBS  F[;PBS
½Fa;PBS  FPBS +

[  ½Fw;[;PBS  F[;PBS½Fw;PBS  FPBS

; (6)
where the subscript w is free tryptophan. The ligands analyzed do not bind to
free tryptophan so any observed quenching of free tryptophan fluorescence is
due to the ligand being in close proximity to tryptophan (effect only observed at
high ligand concentrations). Because there are two antigen/nucleotide binding
sites per antibody, the binding entity (e.g., hapten, nucleotide, or HBL) will be
distributed evenly throughout all available sites. At ligand concentrations equal
to the observed binding constant K0d, there will be a statistical distribution of
three antibody/binder complex subpopulations: 50% of the complex is going
to have be one antibody with one binder, 25% will have two binders (both Fab
arms occupied), and 25%will not have any binder at all. Fluorescence quench-
ing does not distinguish between singly bound and doubly bound antibody/
binder complexes, and because during titration 25% of the antibody is found
uncomplexed, the observed binding constant (K0d) will be higher (suggesting
weaker affinity) than the real binding constant (Kd) by a statistical factor that
reflects the distribution of the ligand between the subpopulations. Therefore,
the actual monovalent binding constant (Kd) is equal to three-fourths of the
observed binding constant K0d as determined by fluorescence quenching.
Accordingly, actual monovalent binding constant Kd can be calculated as
Kd = 3=4K
0
d: (7)
During experiment, IgEDNP was diluted into PBS (pH 7.4) at a concentration
of 100 nM. IgEDNP solution (100 mL) was added to the wells of a 96-well, low
protein binding, plate. Increasing amounts of the heterobivalent ligand were
added to the wells and tryptophan fluorescence of IgEDNP was monitored
(excitation, 280 nm; emission, 335 nm). All fluorescence-binding experiments
were done at least in triplicates.Chemistry & Biology 18, 1179–118ELISA
The wells of a 96-well ELISA plate were incubated with NF-BSA conjugate to
adsorb it onto the surface. The ligand to be assayedwas incubated with IgEDNP
for 30 min prior to being added to the wells. After treating the plate with the
ligand to be assayed and washing, we incubated the plate with a secondary
antibody (anti-mouse IgE from goat) conjugated to horseradish peroxidase
(HRP) purchased from AbD Serotec. After washing, we treated the wells
with Amplex Red, and monitored the HRP-catalyzed hydrolysis of this sub-
strate using fluorescence (excitation, 545 nm; emission, 590 nm). All ELISA
experiments were done at least in triplicates.
RBL Degranulation Assay
RBL cells and IgEDNP were kindly provided by Dr. Wilson (University of New
Mexico). RBL cells were maintained as described previously (Andrews et al.,
2007). For the degranulation assay, cells were plated at 0.5 3 106 cells/ml in
a 96-well plate, and were incubated overnight with 1 mg/ml IgEDNP to saturate
the receptors. Cells were washed immediately before experiments and were
stimulated with the indicated concentrations of NF-BSA. Degranulation was
detected as described earlier (Holowka and Baird, 1996). Triton (1%) was
used to determine the maximum response. For inhibition experiments, cells
were co-incubatedwith increasing concentrations of the heterobivalent ligand.
Monovalent IBA and monovalent NF were used as controls. All degranulation
assays were done at least in triplicates.
Computational Screening for Nucleotide Analogs
Small molecule docking was used to predict the binding modes and relative
affinities of 15 nucleotide analog candidates. We obtained 2D structures
of the ligands (in SDF file format) from the PubChem database (http://
pubchem.ncbi.nlm.nih.gov/). The QuacPac and Omega programs provided
by OpenEye Scientific Software (http://www.eyesopen.com/) were used to
enumerate the potential tautomers, protonation states, and 3D conformations
of each compound. QuacPac was also used to assign AM1-BCC partial
charges to each of the ligands. The antibody structure (PDB code 1MRC)
was prepared for docking using the MOE program (http://www.chemcomp.
com/) to remove crystallographic waters from the structure, and to assign
partial electrostatic charges from the AMBER99 force field. We used the
FRED program from OpenEye to perform the docking; a docking grid that en-
closed the desired binding site with 4.0 A˚ margins was constructed. We per-
formed exhaustive docking of the compounds using the ZapBind Poisson-
Boltzmann implicit solvation scoring function. The top-scoring binding pose
of each compound was saved to the results file, and the list of compounds
was prioritized by the ZapBind score values.
SUPPLEMENTAL INFORMATION
Supplemental Information includes fourteen figures and can be found with this
article online at doi:10.1016/j.chembiol.2011.06.012.
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